Abstract
Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).
Original language | English (US) |
---|---|
Pages (from-to) | 729-730 |
Number of pages | 2 |
Journal | Nature Reviews Drug Discovery |
Volume | 10 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2011 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery